Keyphrases
Toxic Effects
100%
Vemurafenib
100%
Squamous Cell Carcinoma (SqCC)
60%
Rash
40%
Sorafenib
40%
Hand-foot Skin Reaction
40%
Keratosis pilaris
40%
Seborrheic Dermatitis
40%
Molecular Mechanism
20%
Metastatic Melanoma
20%
Phase III Clinical Trial
20%
Tumor Regression
20%
Plantar
20%
Tender
20%
Multikinase Inhibitor
20%
Papules
20%
Reaction Cell
20%
BRAF Inhibitor (BRAFi)
20%
Stage IV Melanoma
20%
BRAF Inhibition
20%
Hyperkeratotic
20%
Eruptive Squamous Cell Carcinomas
20%
Sorafenib Tosylate
20%
Medicine and Dentistry
Vemurafenib
100%
Squamous Cell Carcinoma
80%
Sorafenib
60%
Sequela
40%
Exanthem
40%
Hand Foot Syndrome
40%
Darier's Disease
40%
Seborrheic Dermatitis
40%
Clinical Trial
20%
Dermatological Agent
20%
Tumor Regression
20%
Papule
20%
Metastatic Melanoma
20%
Melanoma
20%